Enhanced sustained release of furosemide in long circulating chitosan-conjugated PLGA nanoparticles

Sapna Kashyap , Amit Singh, Abha Mishra, Vikas Singh


Furosemide (FSM) is commonly used in the treatment of edema associated with congestive cardiac failure, cirrhosis of the liver, renal disease, including the nephrotic syndrome and hypertension. However, in ascites, it is clinically limited due to its frequent dosing and short biological half-life and its prolonged-release preparations are not available. Therefore, the main objective behind the present research work is to develop chitosan coated and conjugated poly (lactic-co-glycolic acid) (PLGA) nanocarriers, to sustain the delivery             of FSM with improved systemic circulation. Emulsion-solvent evaporation technique was used for the preparation of nanoparticles. In-vivo pharmacokinetic study showed 2.6, 3.10, and 4.30 folds enhancement in relative availability of FSM for FSM-PLGA, FSM-chitosan-coated-PLGA and FSM-chitosan-conjugated-PLGA nanoparticles, respectively than FSM. The present research work concluded that FSM loaded chitosan conjugated PLGA nanoparticles could enhance the systemic circulation of FSM with improved pharmacokinetics parameters.


Chitosan; FSM; Nanocarriers; PLGA; Polymeric nanoparticles; Sustained effect.

Full Text:



Devarakonda B, Otto DP, Judefeind A, Hill RA, de Villiers MM. Effect of pH on the solubility and release of FSM from polyamidoamine (PAMAM) dendrimer complexes. Int J Pharm. 2007;345(1-2):142-153.

Goodman LS, Gilman A, Brunton LL. 12th ed. Goodman & Gilman's manual of pharmacology and therapeutics. New York: McGraw-Hill Medical; 2008. pp. 671-702,745-760,770-771.

Giebisch G. The use of diuretic agent as a probe to investigate site and mechanism of ion transport process. Arzneimittelforschung. 1985;35(1A): 336-342.

Tripathi KD. 6th ed. Essentials of Medical Pharmacology. New Delhi: Jaypee Brothers Medical; 2008. pp. 562.

Darandale SS, Vavia PR. Design of a gastroretentive mucoadhesive dosage form of furosemide for controlled release. Acta Pharm Sin B. 2012;2(5):509-517.

Parveen S, Sahoo SK. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharm. 2011;670(2-3):372-383.

Lu JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9(4):325-341.

Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1-18.

Mohamed F, van der Walle CF. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci. 2008;97(1):71-87.

Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid PLGA as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377-1397.

Muthu MS. Nanoparticles based on PLGA and its co-polymer: an overview. Asian J Pharm. 2009;3(4):266-273.

Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm. 2005;290(1-2):137-144.

Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem. 2009;17(8):2950-2962.

Gadad AP, Vannuruswamy G, Chandra PS, Dandagi PM, Mastiholimath VS. Study of different properties and application of Poly lactic-co-glycolic acid (PLGA) nanotechnology: an overview. Indian Drugs. 2012;49(12):5-22.

Pandita D, Kumar S, Lather V. Hybrid poly (lactic-co-glycolic acid) nanoparticles: design and delivery prospectives. Drug Discov Today. 2015; 20(1):95-104.

Alqahtani S, Simon L, Astete CE, Alayoubi A, Sylvester PW, Nazzal S, et al. Cellular uptake, antioxidant and antiproliferative activity of entrapped a-tocopherol and c-tocotrienol in poly (lactic-co-glycolic) acid (PLGA) and chitosan covered PLGA nanoparticles (PLGA-Chi). J Colloids Interface Sci. 2015;445:243-251.

Lim EK, Sajomsang W, Choi Y, Jang E, Lee H, Kang B, et al. Chitosan-based intelligent theragnosis nanocomposites enable pH-sensitive drug release with MRI-guided imaging for cancer therapy. Nanoscale Res Lett. 2013;8(1): 467-478.

Liu B, Wang H, Fan L, Qiu X, Luo Y, Zhou S, et al. Chitosan-modified D-α tocopheryl poly(ethylene glycol) 1000 succinate-b-poly(e-caprolactone-glycolide) nanoparticles for the oral chemotherapy of bladder cancer. J Appl Polym Sci. 2013;130(3):2118-2126.

Chung YI, Kim JC, Kim YH, Tae G, Lee SY, Kim K, et al. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated pluronic on tumor targeting. J Control Release. 2010;143(3):374-382.

Chen LJ, Burka LT. Chemical and enzymatic oxidation of furosemide: formation of pyridinium salts. Chem Res Toxicol. 2007;20(12):1741-1744.

Chronopoulou L, Cutonilli A, Cametti C, Dentini M, Palocci C. PLGA-based nanoparticles: effect of chitosan in the aggregate stabilization. A dielectric relaxation spectroscopy study. Colloids Surf B Biointerfaces. 2012;97:117-123.

Ding SJ. Biodegradation behaviour of chitosan/calcium phosphate composites. J Non-Cryst Solids. 2007;353(24-25):2367-2373.

Ravi Kumar MN, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004;25(10):1771-1777.

Chakravarthi SS, De S, Miller DW, Robinson DH. Comparison of anti-tumor efficacy of paclitaxel delivered in nano-and microparticles. Int J Pharm. 2010;383(1-2):37-44.

Muthu MS, Kutty RV, Luo Z, Xie J, Feng SS. Theranostic vitamin E TPGS micelles of transferrin conjugation for targeted co-delivery of docetaxel and ultra-bright gold nanoclusters. Biomaterials. 2015;39:234-248.

Youm I, Murowchick JB, Youan BB. Entrapment and release kinetics of furosemide from pegylated nanocarriers. Colloids Surf B Biointerfaces. 2012;94:133-142.

Muthu MS, Rawat MK, Mishra A, Singh S. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomedicine. 2009;5(3):323-333.

Abou-Auda HS, Al-Yamani MJ, Morad AM, Bawazir SA, Khan SZ, Al-Khamis KI. High-performance liquid chromatographic determination of furosemide in plasma and urine and its use in bioavailability studies. J Chromatogr B Biomed Sci Appl. 1998;710(1-2):121-128.

Mills CD, Whitworth C, Rybak LP, Henley CM. Quantification of furosemide from serum and tissues using high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997;701(1):65-70.

Shin S, Oh J, Lee Y, Choi K, Choi J. Enhanced dissolution of furosemide by coprecipitating or cogrinding with crospovidone. Int J Pharm. 1998;175(1):17-24.

Govender T, Riley T, Ehtezazi T, Garnett MC, Stolnik S, Illum L, et al. Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Pharm. 2000;199(1):95-110.

Muller RH. Charge determination. Muller RH CRC press: Boca Raton; 1991. pp. 57-97.

Betancourt T, Brown B, Brannon-peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomed. 2007;2(2):219-232.

Chakravarthi SS, Robinson DH. Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int J Pharm. 2011;409(1-2):111-120.

Greenblatt DJ. Elimination half-life of drugs: value and limitations. Annu Rev Med. 1985;36:421-427.


  • There are currently no refbacks.

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.